Table 2

The Study Results
Study group (group A) Control group (group B) p-value Odds ratio 95% CI
Number of patients -at 1st month 26 29 0.2 - -
-at 3rd month 26 25 1.00
-at 6th month 16 14 0.79
-at 12th month 7 7 1.00
VA (logMAR ± SD) -at 3rd m. 0.09 ± 0.20 0.09 ± 0.09 0.99 - -
-at 6th m. 0.05 ± 0.06 0.04 ± 0.06 0.60
-at 12th m. 0.04 ± 0.05 0.03 ± 0.05 0.91
CMT (microns ± SD) -at 3rd m. 220.65 ± 94.37 243.84 ± 76.13 0.34 - -
-at 6th m. 193.20 ± 46.38 183.22 ± 22.59 0.41
-at 12th m. 180.00 ± 15.05 186.22 ± 20.62 0.42
Patients with subretinal fluid (number of patients)
-at 1st month 22 23 0.73 - -
-at 2nd month 13 14 0.78 - -
-at 3rd month 3 10 0.027 0.196 0.046-0.830
Follow-up time (m ± SD) 9.04 ± 6.69 8.14 ± 8.69 0.67 - -
FA leakage at 3rd m. (patients) 3 10 0.027 0.196 0.046 - 0.830
- inkblot leakage 2 9 - - -
- smokestack leakage 1 1 0.94 - -
Laser or PDT (number of patients) 4 11 0.03 0.231 0.061 - 0.872
Recurrence (number of patients) 1 2 0.29 - -

Study group (group A): the group received antioxidant tablets.

Control group (group B): the group received placebo tablets.

CI = confidence interval.

VA = visual acuity, logMAR = logarithm of minimum angle of resolution.

SD = standard deviation.

m = month, CMT = central macular thickness.

FA = fluorescein angiography, PDT = photodynamic therapy.

Ratanasukon et al.

Ratanasukon et al. BMC Ophthalmology 2012 12:20   doi:10.1186/1471-2415-12-20

Open Data